Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Multi-center Phase II Study of Subcutaneous Alemtuzumab Combined With Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allogeneic Stem-cell Transplantation, in Chronic Lymphocytic Leukemia Which is Associated With 17p Deletion or is Refractory to Fludarabine

NCT01392079 is registered in ClinicalTrials.gov with University of Ulm as lead sponsor.

NCT NCT01392079
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01392079 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Multi-center Phase II Study of Subcutaneous Alemtuzumab Combined With Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allogeneic Stem-cell Transplantation, in Chronic Lymphocytic Leukemia Which is Associated With 17p Deletion or is Refractory to Fludarabine
Lead sponsor
University of Ulm
Phase
Phase 2
Overall status
Completed
Start date
February 29, 2008
Completion date
March 31, 2016
Enrollment
135 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia